Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial

Abstract

AbstractMost multigene mutation tests require tissue specimens. However, cytological specimens are easily obtained in the clinical practice and provide high‐quality DNA and RNA. We aimed to establish a test that utilizes cytological specimens and performed a multi‐institutional study to investigate the performance of MINtS, a test based on next‐generation sequencing. A standard procedure for specimen isolation was defined. The specimens were considered suitable for the test if >100 ng DNA and >50 ng RNA could be extracted from them. In total, 500 specimens from 19 institutions were investigated. MINtS detected druggable mutations in 63% (136 of 222) of adenocarcinomas. Discordant results between MINtS and the companion diagnostics were observed in 14 of 310 specimens for the EGFR gene, and 6 of 339 specimens for the ALK fusion genes. Confirmation by other companion diagnostics for the EGFR mutations or the clinical response to an ALK inhibitor all supported the results obtained by MINtS. MINtS along with the isolation procedure presented in the current study will be a platform to establish multigene mutation tests that utilize cytological specimens. UMIN000040415.